Balyasny Asset Management
ELDN icon

Balyasny Asset Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Balyasny Asset Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-61,520
Closed -$209K – 2957
2025
Q1 		$209K Buy
61,520
+28,897
+89% +$119K ﹤0.01% 2576
2024
Q4 		$134K Buy
+32,623
New +$129K ﹤0.01% 2580

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Balyasny Asset Management's ELDN Position: Q2 2025 in Review

Balyasny Asset Management sold out of Eledon Pharmaceuticals (ELDN) in Q2 2025, closing a stake of 61,520 shares — an estimated $209K sold.

Balyasny Asset Management first reported a position in ELDN in Q4 2024 and held it in 2 quarters. The position peaked at $209K in Q1 2025. 85 funds tracked by Wall St. Rank hold ELDN as of Q2 2025.

  • Balyasny Asset Management reported no remaining Eledon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 61,520 Eledon Pharmaceuticals shares in Q2 2025, an estimated $209K.
  • Balyasny Asset Management first reported a position in Eledon Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Balyasny Asset Management's Eledon Pharmaceuticals position peaked at $209K in Q1 2025.
  • 85 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.